Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Rare Diseases

Neuromuscular disorders include many rare conditions, such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy, that adversely impact respiratory health.

Tests offered

The Wal-yan Respiratory Research Centre offers a broad range of outpatient and portable tests for those affected by chronic respiratory conditions.

Research

Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccines among pregnant women (the EPIC study): study protocol

Influenza and COVID-19 infections during pregnancy may have serious adverse consequences for women as well as their infants. However, uptake of influenza and COVID-19 vaccines during pregnancy remains suboptimal. This study aims to assess the effectiveness of a multi-component nudge intervention to improve influenza and COVID-19 vaccine uptake among pregnant women. 

News & Events

Worried about your child getting coronavirus? Here’s what you need to know

Comparatively few children have tested positive for coronavirus (COVID-19). Here’s what we know so far about how children are affected.

Impact Report 2025

View The Kids Research Institute Australia's 2025 Impact Report

News & Events

Embrace Big Idea 2023 winners announced

Photo (clockwise from top-left): Dr Craig Taplin, Mx Rigel Paciente, Ms Heather Roby, Dr Keely Bebbington, Dr Alix Woolard.

News & Events

Youth Sanctuary to open in Subiaco

Mental Health Minister Amber-Jade Sanderson presents funding that will enable the Youth Sanctuary to open later this year.

Phage WA Artificial Intelligence Team

Our team uses AI to quickly analyse large amounts of genetic data to help discover alternate medications and improve existing treatments.

Ivacaftor or lumacaftor/ivacaftor treatment does not alter the core CF airway epithelial gene response to rhinovirus

We tested the hypothesis that treatment of CF epithelial cells with ivacaftor (Iva) or ivacaftor/lumacaftor (Iva/Lum) would improve control of rhinovirus infection.